Market watch ptgx
Web15 mrt. 2024 · View the latest Protagonist Therapeutics Inc. (PTGX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Web17 mrt. 2024 · The latest price target for Protagonist Therapeutics ( NASDAQ: PTGX) was reported by HC Wainwright & Co. on Thursday, November 10, 2024. The analyst firm set a price target for 33.00 expecting...
Market watch ptgx
Did you know?
Web4 apr. 2024 · Item 8.01. Other Events. Underwriting Agreement On April 4, 2024, Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (collectively, … Web7 mrt. 2024 · Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from its collaboration with Janssen Biotech Inc, a part of Johnson & Johnson (NYSE: …
Web24 feb. 2024 · Protagonist Therapeutics Inc.’s market cap currently stands at around $770.75 million, with investors looking forward to this quarter’s earnings report slated for … WebQuand je leur dis que je suis traductrice, les gens me demandent souvent « Donc vous faites quoi exactement ? ». Découvrez, dans le premier article (en…
Web12 apr. 2024 · PTGX Signals & Forecast Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an … Web10 apr. 2024 · PTGX Complete Protagonist Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Protagonist Therapeutics Inc. analyst estimates, including PTGX earnings per … MRNA Complete Moderna Inc. stock news by MarketWatch. View real-time stock … PLPL Complete Plandai Biotechnology Inc. stock news by MarketWatch. View … PIRS Complete Pieris Pharmaceuticals Inc. stock news by MarketWatch. View … ENPH Complete Enphase Energy Inc. stock news by MarketWatch. View real …
Web28 dec. 2024 · The shares of Fate Therapeutics (FATE) rose nearly 6% yesterday.
Web17 mrt. 2024 · PTGX’s current price about 22.34% and 49.02% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently … sanford maine assessing dataWeb20 uur geleden · Get Protagonist Therapeutics Inc (PTGX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. short dark purple dressesWeb5 apr. 2024 · (RTTNews) - Shares of Protagonist Therapeutics, Inc. (PTGX) are falling more than 8% Wednesday morning after the company priced its previously-announced public … short dark triad insults scaleWeb13 apr. 2024 · Furthermore, Protagonist Therapeutics Inc. (PTGX)’s beta value is 1.97, and its average true range (ATR) is 1.34. The company’s stock has been forecasted to trade … short dark red dressesWeb13 apr. 2024 · The stock has a market capitalization of $5.23 billion, a price-to-earnings ratio of 9.06, a price-to-earnings-growth ratio of 0.72 and a beta of 1.14. Academy Sports and Outdoors Increases Dividend sanford maine assessor databaseWebPotomac Watch Podcast; Foreign ... PTGX will report Q1 earnings on 08/09/2024 . Q1 2024 Estimate ... comprehensive quotes and volume reflect trading in all markets and are … short dark hairstyles with highlightsWeb5 apr. 2024 · NEWARK, CA / ACCESSWIRE / April 4, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share. short dark triad scale